Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
Status:
Completed
Trial end date:
2017-03-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of long-term therapy
with retigabine administered as adjunctive therapy in adult epilepsy patients with
partial-onset seizures, who completed the VRX-RET-E22-301 double-blind study. The efficacy of
long-term treatment with retigabine and patient quality of life will also be assessed.